Canaccord Genuity Reiterates a 'Buy' on Teva Pharma (TEVA); View Post MNTA Management Meeting

Canaccord Genuity reiterates a 'Buy' on Teva Pharma (NASDAQ: TEVA) price target of $52.00.

Canaccord analyst says, "We continue to like TEVA here. We’re introducing new analysis looking at the value of TEVA shares ex-US Copaxone following ongoing investor discussions, our meeting Friday with Momenta (Nasdaq: MNTA) management, ECTRIMS takeaways and what continues to be ongoing speculation around potential impact from BG-12. The bottom line: we believe removing US Copaxone (and NPV) paints a more stable earnings picture, provides an attractive five-year 11% EPS CAGR, and leaves upside optionality on a host of things that may have potential to preserve franchise value. Overall, our analysis keeps us comfortable with upside. "

For more ratings news on Teva Pharma click here and for the rating history of Teva Pharma click here.

Shares of Teva Pharma closed at $39.16 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Holcim to acquire Fermacell from James Hardie for EUR 840M
• Firm Capital Apartment REIT posts Q2 loss, plans name change